Eledon Pharmaceuticals, Inc. (ELDN) NASDAQ
3.49
-0.04(-1.13%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.49
-0.04(-1.13%)
Currency In USD
Address
19900 MacArthur Boulevard
Irvine, CA 92612
United States of America (the)
Phone
949 238 8090
Website
Sector
Healthcare
Industry
Biotechnology
Employees
31
First IPO Date
September 17, 2014
| Name | Title | Pay | Year Born |
| David-Alexandre C. Gros | Chief Executive Officer & Non Independent Director | 984,408 | 1972 |
| Bryan E. Smith | General Counsel, Corporate Secretary & Chief Compliance Officer | 377,136 | 1980 |
| Paul Sean Little | Chief Financial Officer | 717,378 | 1965 |
| Steven N. Perrin | President, Chief Scientific Officer & Non Independent Director | 792,156 | 1966 |
| David Hovland | Chief Regulatory Officer | 0 | N/A |
| Eliezer Katz | Chief Medical Officer | 0 | N/A |
| John Herberger | Vice President of Technical Operations | 0 | N/A |
| Marina Escudero | Vice President & Head of Clinical Operations | 0 | N/A |
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.